Zobrazeno 1 - 10
of 224
pro vyhledávání: '"Sunita D. Nasta"'
Autor:
Guido Ghilardi, Luca Paruzzo, Vrutti Patel, Jakub Svoboda, Emeline R. Chong, Eugenio Fardella, Elise A. Chong, Giulia Gabrielli, Sunita D. Nasta, Daniel J. Landsburg, Jordan Carter, Raymone Pajarillo, Stefan K. Barta, Griffin White, Elizabeth Weber, Ellen Napier, David L. Porter, Alfred L. Garfall, Stephen J. Schuster, Marco Ruella
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-5 (2024)
Abstract Bendamustine has been retrospectively shown to be an effective and safe lymphodepletion regimen prior to the anti-CD19 chimeric antigen receptor T cell (CART) products tisagenlecleucel and axicabtagene ciloleucel, as well as the anti-BCMA CA
Externí odkaz:
https://doaj.org/article/7841086f48d141fcacd16214fbafb379
Autor:
Nikhil Yegya-Raman, Christopher M. Wright, Michael J. LaRiviere, Jonathan A. Baron, Daniel Y. Lee, Daniel J. Landsburg, Jakub Svoboda, Sunita D. Nasta, James N. Gerson, Stefan K. Barta, Elise A. Chong, Stephen J. Schuster, Amit Maity, Andrea Facciabene, Ima Paydar, John P. Plastaras
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 39, Iss , Pp 100587- (2023)
Background and purpose: CD19-targeting chimeric antigen receptor T-cell (CART) therapy is a promising treatment for relapsed/refractory non-Hodgkin lymphoma, but most patients experience post-CART progression. We describe our institutional experience
Externí odkaz:
https://doaj.org/article/ec50e35247a94a979e90b1070080c98a
Autor:
Emily C. Ayers, Sunita D. Nasta
Publikováno v:
European Medical Journal, Vol 3, Iss 4, Pp 40-48 (2018)
Immunotherapy has revolutionised the treatment of haematologic malignancies. Patients with relapsed/refractory non-Hodgkin’s lymphoma have poor response rates and short survival times when conventional cytotoxic chemotherapies are used. Immunothera
Externí odkaz:
https://doaj.org/article/fe39e6ded04d46c7a5d0508775c1e3d6
Autor:
Anthony R. Mato, Chadhi Nabhan, Meghan C. Thompson, Nicole Lamanna, Danielle M. Brander, Brian Hill, Christina Howlett, Alan Skarbnik, Bruce D. Cheson, Clive Zent, Jeffrey Pu, Pavel Kiselev, Andre Goy, David Claxton, Krista Isaac, Kaitlin H. Kennard, Colleen Timlin, Daniel Landsburg, Allison Winter, Sunita D. Nasta, Spencer H. Bachow, Stephen J. Schuster, Colleen Dorsey, Jakub Svoboda, Paul Barr, Chaitra S. Ujjani
Publikováno v:
Haematologica, Vol 103, Iss 5 (2018)
Clinical trials that led to ibrutinib’s approval for the treatment of chronic lymphocytic leukemia showed that its side effects differ from those of traditional chemotherapy. Reasons for discontinuation in clinical practice have not been adequately
Externí odkaz:
https://doaj.org/article/a606b178c28248cb9a40c8b3853c496c
Autor:
Daniel J Landsburg, Sunita D Nasta, Jakub Svoboda, James N Gerson, Stephen J Schuster, Stefan K Barta, Elise A Chong, Heather Difilippo, Elizabeth Weber, Kathleen Cunningham, Christopher Catania, Alfred L Garfall, Edward A Stadtmauer, Noelle V Frey, David L Porter
Publikováno v:
Transplantation and Cellular Therapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::decf557061fe4ba8d9c9d46743390395
https://doi.org/10.1016/j.jtct.2023.05.011
https://doi.org/10.1016/j.jtct.2023.05.011
Autor:
Nausheen Ahmed, William Wesson, Muhammad Umair Mushtaq, David L. Porter, Sunita D. Nasta, Jamie Brower, Veronika Bachanova, Marie Hu, Loretta J. Nastoupil, Olalekan O. Oluwole, Vivek G. Patel, Caspian Oliai, Peter A. Riedell, Michael R. Bishop, Gunjan L. Shah, Miguel-Angel Perales, Levanto Schachter, Richard T. Maziarz, Joseph P. McGuirk
Publikováno v:
Transplantation and Cellular Therapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3598291d5ad7a5eca07b5516524b1341
https://doi.org/10.1016/j.jtct.2023.04.019
https://doi.org/10.1016/j.jtct.2023.04.019
Autor:
Stephen J. Schuster, Kristy M. Walsh, Anthony R. Mato, Sunita D. Nasta, Jakub Svoboda, Nicole A. Aqui, Tahamtan Ahmadi, Elise A. Chong
Purpose: Lenalidomide, an immunomodulatory agent that enhances antibody-dependent cell-mediated cytotoxicity, has the potential to synergize with rituximab, an anti-CD20 mAb. We hypothesized that the addition of lenalidomide to rituximab would improv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d3f16637b4e5c8a52d649c41feca4f5
https://doi.org/10.1158/1078-0432.c.6523182
https://doi.org/10.1158/1078-0432.c.6523182
Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy
Autor:
Simon F. Lacey, Stephen J. Schuster, Elise A. Chong, Sunita D. Nasta, Jakub Svoboda, Marco Ruella, Siddharth Bhattacharyya, E. John Wherry, Cécile Alanio, Daniel J. Landsburg
Publikováno v:
Blood
CD19-directed chimeric antigen receptor–modified (CAR T) T cells achieve durable remissions in about 30% to 40% of relapsed/refractory large B-cell lymphomas. T-cell exhaustion and/or an immunosuppressive tumor microenvironment may contribute to CA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fe2e8ebe2148e07ce3d673a7137e5f8
https://doi.org/10.1182/blood.2021012634
https://doi.org/10.1182/blood.2021012634
Autor:
Daniel J. Landsburg, Jennifer J.D. Morrissette, Stephen J. Schuster, Sunita D. Nasta, James N. Gerson, Stefan K. Barta, Jakub Svoboda, Elise A. Chong, Megan S. Lim
Publikováno v:
Oncotarget. 13
Comprehensive genomic analyses of tumor biopsies from patients with newly-diagnosed germinal center B cell (GCB) diffuse large B cell/high grade B cell lymphoma (DLBCL/HGBL) have identified molecular subtypes predictive of inferior survival, which ar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::560240aacf97de1e9750f2d91be7c1bf
https://pubmed.ncbi.nlm.nih.gov/36441737
https://pubmed.ncbi.nlm.nih.gov/36441737
Publikováno v:
Expert Review of Precision Medicine and Drug Development. 6:317-332
Non-Hodgkin lymphoma is a disease spectrum of multiple subtypes with many potential targets. Given the heterogeneity and evolving landscape for targeted therapy, incorporation of therapeutics in th...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d405faf64f1ae5687a1ba6038f3905a
https://doi.org/10.1080/23808993.2021.1967142
https://doi.org/10.1080/23808993.2021.1967142